XML 66 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and License Agreements - Bristol-Myers Squibb Company - Additional Information (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Apr. 25, 2017
USD ($)
Target
Jul. 07, 2014
USD ($)
Target
Term
Mar. 31, 2020
USD ($)
Jan. 31, 2018
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Feb. 29, 2020
USD ($)
Nov. 30, 2017
USD ($)
Mar. 17, 2017
Target
Dec. 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Deferred revenue         $ 94,063 $ 212,315 $ 301,326          
Bristol Myers Squibb                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Deferred revenue         $ 41,900              
Collaborative Arrangement | Bristol Myers Squibb                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Collaboration target research term   2 years                    
Number of additional collaboration target | Target   2                    
Research terms         Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.              
Extension of research term for each collaboration target   1 year                    
Upfront payment received $ 200,000 $ 50,000                    
Contingent milestone payments receivable         $ 1,300,000     $ 10,000     $ 15,000 $ 10,000
Number of research targets selected | Target 8                      
Total transaction price   304,700                    
Upfront fee received   250,000                    
Research and development service fees   17,700                    
Milestone payment received     $ 10,000 $ 12,000                
Milestone payments received         297,000              
Deferred revenue         $ 41,900 $ 119,900            
Collaborative Arrangement | Bristol Myers Squibb | Pre Clinical Candidate                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Contingent milestone payments receivable                     $ 2,000  
Collaborative Arrangement | Bristol Myers Squibb | Third And Fourth Target                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Target selection fee   $ 25,000                    
Collaborative Arrangement | Bristol Myers Squibb | New Drug Application for CTLA-4                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Contingent milestone payments receivable                 $ 10,000      
Collaborative Arrangement | Maximum | Bristol Myers Squibb                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of oncology target | Target   4                    
Number of collaboration target | Target   2                    
Period of nomination of additional target from effective date   5 years                    
Times of increments for extended collaboration target research time | Term   3                    
Collaborative Arrangement | Maximum | Bristol Myers Squibb | Each Of Two Additional Targets                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Contingent milestone payments receivable   $ 25,000                    
Collaboration and License Agreement | Maximum | Bristol Myers Squibb                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of additional collaboration target | Target                   8